Coronado Biosciences Inc. announced the publication of data demonstrating that the Bcl-2 inhibitor, Apogossypol, effectively killed a variety of cancer cells in vitro while demonstrating less toxicity than Gossypol in vivo in mice. Published online in Blood (Jan. 17, DOI 10.1182/blood-2007-09-113647) by the Burnham Institute’s president and CEO, John Reed, M.D., Ph.D.

Bacteria that eat sugar and release cavity-causing acid onto teeth may soon be made dramatically more vulnerable to their own acid. Researchers have identified key genes and proteins that, if interfered with, can take away the ability of a key bacterial species to thrive as its acidic waste builds up in the mouth.The ability of Streptococcus mutans (S. mutans) to survive in acid is one reason that the species is the main driver of tooth decay worldwide.

Each year, cardiovascular disease kills more Americans than cancer. And while most people are aware that lifestyle choices such as eating right, getting enough exercise and quitting smoking can help prevent cardiovascular disease, they may not know that by just brushing and flossing their teeth each day, they might also be avoiding this potentially lethal condition.

ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, announced it has completed its Pre-IND (Investigational New Drug) meeting with the FDA to discuss the upcoming IND submission for ARH460-16-2, its lead CD44 Cancer Stem Cell Program. ARH460-16-2 is an anti-cancer antibody targeting a novel epitope of CD44 found in hematological and solid cancers, including breast, colon and prostate.

People who receive high doses of the chemotherapy drug methotrexate to treat a certain type of brain tumor appear to live longer than people receiving other treatments, according to research published in the January 29, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology.

An independent investigator clinical trial has shown atrial fibrillation (AF) is effectively treated using the Epicor(TM) Cardiac Ablation System, when treated concomitantly to corrective heart surgery. The trial results were published in the December edition of The Annals of Thoracic Surgery. St. Jude Medical, Inc. (NYSE:STJ) manufactures and distributes the Epicor system.

About nine percent of teenagers may have metabolic syndrome, a clustering of risk factors that put them on the path toward heart disease and diabetes in adulthood. This shocking statistic represents some of the first concentrated efforts to define and measure metabolic syndrome in children and adolescents - a necessary starting point for combating the problem, but one that has proven even trickier in youth than it has been in adults.

Compugen Ltd. (NASDAQ:CGEN) announced the results from initial in-vivo validation studies of CGEN-855A and CGEN-855B, two novel peptide agonists of the FPRL1 G-protein coupled receptor (GPCR), which may serve as anti-inflammatory and cardio-protective drug candidates. CGEN-855A and CGEN-855B were discovered using the Company’s previously announced GPCR ligand discovery platform.

Compugen Ltd. (NASDAQ:CGEN) announced the results from initial in-vivo validation studies of CGEN-855A and CGEN-855B, two novel peptide agonists of the FPRL1 G-protein coupled receptor (GPCR), which may serve as anti-inflammatory and cardio-protective drug candidates. CGEN-855A and CGEN-855B were discovered using the Company’s previously announced GPCR ligand discovery platform.

An independent investigator clinical trial has shown atrial fibrillation (AF) is effectively treated using the Epicor(TM) Cardiac Ablation System, when treated concomitantly to corrective heart surgery. The trial results were published in the December edition of The Annals of Thoracic Surgery. St. Jude Medical, Inc. (NYSE:STJ) manufactures and distributes the Epicor system.